1.19
-0.05 (-4.03%)
| Penutupan Terdahulu | 1.24 |
| Buka | 1.17 |
| Jumlah Dagangan | 855,010 |
| Purata Dagangan (3B) | 1,200,232 |
| Modal Pasaran | 60,384,292 |
| Harga / Buku (P/B) | 0.390 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 May 2025 - 19 May 2025 |
| EPS Cair (TTM) | -2.34 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.24% |
| Nisbah Semasa (MRQ) | 6.15 |
| Aliran Tunai Operasi (OCF TTM) | -88.22 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -54.51 M |
| Pulangan Atas Aset (ROA TTM) | -35.66% |
| Pulangan Atas Ekuiti (ROE TTM) | -59.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Cabaletta Bio, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.10% |
| % Dimiliki oleh Institusi | 79.61% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 31 Dec 2024 | 2,760,888 |
| Superstring Capital Management Lp | 31 Dec 2024 | 822,293 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 25.00 (HC Wainwright & Co., 2,000.84%) | Beli |
| Median | 22.00 (1,748.74%) | |
| Rendah | 3.00 (Wells Fargo, 152.10%) | Pegang |
| Purata | 16.00 (1,244.54%) | |
| Jumlah | 4 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 1.17 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Guggenheim | 01 Apr 2025 | 23.00 (1,832.77%) | Beli | 1.17 |
| HC Wainwright & Co. | 01 Apr 2025 | 25.00 (2,000.84%) | Beli | 1.17 |
| 18 Feb 2025 | 25.00 (2,000.84%) | Beli | 2.33 | |
| Morgan Stanley | 01 Apr 2025 | 22.00 (1,748.74%) | Beli | 1.17 |
| UBS | 01 Apr 2025 | 7.00 (488.24%) | Beli | 1.17 |
| Wells Fargo | 01 Apr 2025 | 3.00 (152.10%) | Pegang | 1.17 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |